Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Therapeutic misconception—a false belief that individuals will benefit from participating in research—can bias informed consent. Ethics consultants can help by engaging participants’ and researchers’ understandings of risks and benefits and by asking good questions about the influences of researchers’ enthusiasm.
AMA J Ethics. 2018;20(11):E1100-1106. doi:
10.1001/amajethics.2018.1100.
Clinicians can practice disability humility by developing social understandings of disability. This can help clinicians improve communication and express respect for patients’ authority about their experiences.
AMA J Ethics. 2018;20(12):E1181-1187. doi:
10.1001/amajethics.2018.1181
Physicians should provide women considering abortion after Down syndrome screening with unbiased information and not attempt to influence their decision.
AMA J Ethics. 2016;18(4):359-364. doi:
10.1001/journalofethics.2016.18.4.ecas1-1604.